

08/29/2022

Hepatitis C Treatment Coverage and PDL Update Delayed to Jan. 1, 2023

Background:

HHSC will postpone the Preferred Drug List (PDL) changes related to Hepatitis C treatment coverage to Jan. 1, 2023. We previously announced on Aug. 11 (“Hepatitis C Treatment Coverage and PDL Update Scheduled for Sept. 1”) that these changes would begin on Sept. 1, 2022.

Key Details:

Beginning Jan. 1, 2023, HHSC will designate one medication as the primary preferred direct-acting antiviral (DAA) drug option for treating Hepatitis C infection. HHSC will set all other DAA drugs on the Medicaid formulary as non-preferred.

HHSC will publish an update to the Texas Medicaid Preferred Drug List (PDL) on Jan. 1, 2023, to designate preferred and non-preferred options for DAA treatment. We will provide a follow-up notice with specific NDC information ahead of the Jan. 1 implementation date. Additionally, the date for retiring the “Antiviral Agents for Hepatitis C Virus” clinical prior authorization forms (HHS Form 1335 and 1342) will also be postponed to Jan. 1 to align with PDL changes for DAA drugs.

MCOs must notify their providers and members regarding the changes to Hepatitis C treatment coverage.

Contact:

vdp-formulary@hhsc.state.tx.us

Type: Informational

To: CHIP; STAR; STAR+PLUS; STARHEALTH; STAR_KIDS

From: VDP